TIDMDVRG
RNS Number : 0320U
Deepverge PLC
31 March 2021
31 March 2021
DeepVerge PLC
("DeepVerge" or "Company")
DeepVerge Investor Presentation
Project Updates on Labskin, Modern Water, Skin Trust Club
DeepVerge (LSE:DVRG.L), the environmental and life science AI
company , is pleased to provide an update ahead of Gerry Brandon,
the CEO of DeepVerge presentation relating to Project Updates -
Labskin, Skin Trust Club, Modern Water - Wastewater & Breath
Test via the Investor Meet Company platform on 31st Mar 2021 at
1:30pm BST.
-- Incredibly busy period with continued growth across all business divisions:
-- FY 2020 unaudited - organic growth - GBP4.4m
-- FY 2020 aggregated revenues GBP6.1m (unaudited)
-- Dec 2020: Cash & Cash Equivalent GBP2.97m
-- Post Dec 2020: GBP650,740 in exercised warrants
-- FY 2021 guidance remains at GBP10m with GBP3.6m already
received in Modern Water orders in Q1
-- The Labskin Division has sealed its reputation as a leading
diagnostics partner with global partners and new service
offerings
-- We work with 18 of the top 20 global pharma companies.
-- Virtual clinical trials with remote collection of human
volunteer's skin microbiome
-- New solution for the collection of volunteer microbiomes to
allow for lab controlled clinical trials of advanced skin models
(pigmented, acne, atopic dermatitis, psoriasis) and human
microbiomes
-- As the data bank of remote volunteers grow the higher the
accuracy and increased reliability of virtual product testing can
be provided to clients eliminating early human trial and error
testing and faster time to market
-- Building of a data repository to allow AI modelling of skin
conditions and ingredient effects
-- Launch of Skin Trust Club Artificial Intelligent (A.I.)
Skincare App and Home Test Kit
-- 2,000 members in the Alpha test with more than 5,000 before
we stopped accepting for the Beta of which we will throttle back to
complete.
-- Self-administered skin swab from home-test-kit allows the
clinical trial or Skin Trust Club participant to conduct a simple
test without interaction
-- DNA test that generates a report consumers can use to manage
their custom skincare regimen. Analysis of skin attributes provides
information to create hundreds of different product combinations to
suit a persons unique skin microbiome
-- As the data bank of remote volunteers grow the higher the
accuracy and increased reliability of virtual product testing can
be provided to clients eliminating early human trial and error
testing and faster time to market
-- Environmental Health division also continues to grow apace
with new equipment, solutions, labs and services creating a strong
$5m (GBP3.7m) sales pipe for Microtox and Microtrace in Q1
alone:
-- New equipment rolling off production lines on three
continents to meet demand across the Microtox and MicroTrace range
with new range of real-time surveillance services in Water Quality
Monitoring
-- New solutions to detect contaminants of concern and forever
chemicals through Microsaic systems, mass spectroscopy-based
identification systems and our work with the Aptamer Group
-- Two New Containment Level 3 (Virus) level labs at our York UK
facility
-- New services to detect dangerous pathogens, including
contagious infections as well as community detection of opioids
-- Initial data from ongoing Phase III COVID-19 detection
studies demonstrates ability to identify and detect the virus
-- Public Health England access to the SARS-CoV-2 virus at
Category 3 lab with University of Aberdeen, Genoa, Italy and
Liverpool University
-- Identified the virus S-Protein in quantities at 40 femtogram per millilitre ("Fg/mL")
-- Close to 100% sensitivity and specificity on DeepVerge's
Microtox(R) BT nano-optofluidic chip
-- 40 subject breath test clinical trial concluded at Royal
College of Surgeons, Ireland
-- 16 independently confirmed as COVID-19 positive with PCR tests
-- Breath samples were tested on the Microtox(R) BT
nano-optofluidic chip surface with Affimer(R) reagents ("Avacta
Group") and Optimers ("Aptamer Group")
-- Detection of the live virus confirmed indicating 9 times
increase in digital spectrum signal on the Microtox(R) BT compared
to control
-- Microtox(R) BT delivered results in under 60 seconds from breath samples
-- Subject to completion of additional human trials, the
Microtox(R) BT would be expected to meet the criteria for UK,
MHRA's Target Product Profile Rapid Breath Test which would enable
us to roll out the COVID19 and other pathogen breath tests later
this year
-- 2021 looks to be a promising year for DeepVerge with progress
ramping up and particularly strong interest from China for our
Microtox products, as well as our new Labskin offerings.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet DEEPVERGE PLC via:
https://www.investormeetcompany.com/deepverge-plc/register-investor
Investors who already follow DEEPVERGE PLC on the Investor Meet
Company platform will automatically be invited.
+44 (0) 734 0055
DeepVerge plc Gerry Brandon 648
SPARK Advisory Partners
Limited Neil Baldwin/Andrew +44 (0) 113 370
(Nominated Adviser) Emmott 8974
Turner Pope Investments Andy Thacker/Zoe +44 (0) 20 3657
(TPI) Limited (Broker) Alexander 0050
About DeepVerge plc (www.deepverge.com)
DeepVerge is an environmental and life science group of
companies that develops and applies AI and IoT technology to
analytical instruments and the data they generate, for the analysis
and identification of bacteria, virus and toxins. DeepVerge is
utilising artificial intelligent data analytics to prove
scientifically the impact of skincare product claims on the skin
microbiome for clients including most of the top 20 global cosmetic
companies and to detect remotely, and identify in real-time,
dangerous pathogens in wastewater treatment plants, drinking water,
rivers, lakes and reservoirs.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDSDEFASEFSEFD
(END) Dow Jones Newswires
March 31, 2021 02:00 ET (06:00 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From Mar 2023 to Mar 2024